Jeon Gyun-Ho, Lee Dae Sim, Byun Jung Mi, Kim Ki Tae, Jeong Dae Hoon
Department of Obstetrics and Gynecology, Haeundae Paik Hospital, Busan, Republic of Korea.
Paik Institute for Clinical Research, Busan, Republic of Korea.
J Obstet Gynaecol Res. 2021 Jan;47(1):119-127. doi: 10.1111/jog.14439. Epub 2020 Aug 23.
V-set and immunoglobulin domain-containing 4 (VSIG4) is a potent negative regulator of T-cell responses and is suggested to regulate antitumor immunity. This study investigates whether VSIG4 is significantly expressed in endometriosis patients and the association between VSIG4 levels and serum cancer antigen (CA)-125 levels, VSIG4 levels and endometriosis severity.
Tumor tissues and peripheral blood samples were obtained during surgery from 42 endometriotic cyst and 21 nonendometriotic tumor patients. The levels of VSIG4 mRNA, VSIG4 protein expression in tumor tissue and serum soluble VSIG4 concentration were compared between the two groups. After dividing the cohort using the optimized cut-off values obtained by receiver operating characteristic curve analysis, we examined the association between VSIG4 levels and serum CA-125 levels, VSIG4 levels and the factors indicating endometriosis severity.
The expressions of VSIG4 mRNA, VSIG4 protein and serum VSIG4 concentration were significantly increased in the endometriotic cyst group compared with the control group (P = 0.001, 0.002 and 0.049, respectively). The optimized VSIG4 cut-off values for endometriosis prediction were 0.71, 0.32 and 144.37 pg/mL, respectively. After cohort division using these values, high VSIG4 levels group showed significantly elevated CA-125 compared with low VSIG4 level group (P = 0.010, 0.043 and 0.039, respectively). There was no association between VSIG4 levels and the factors indicating endometriosis severity.
The expression of VSIG4 in endometriosis patients is increased compared with nonendometriotic tumor patients, and higher VSIG4 levels are significantly associated with higher serum CA-125 levels. VSIG4 may be importantly involved in the immunological alteration of endometriosis.
含V结构域和免疫球蛋白结构域4（VSIG4）是T细胞反应的一种有效负调节因子，提示其可调节抗肿瘤免疫。本研究调查VSIG4在子宫内膜异位症患者中是否显著表达，以及VSIG4水平与血清癌抗原（CA）-125水平、VSIG4水平与子宫内膜异位症严重程度之间的关联。
在手术过程中从42例子宫内膜异位囊肿患者和21例非子宫内膜异位肿瘤患者获取肿瘤组织和外周血样本。比较两组之间VSIG4 mRNA水平、肿瘤组织中VSIG4蛋白表达及血清可溶性VSIG4浓度。使用通过受试者工作特征曲线分析获得的优化临界值对队列进行划分后，我们检测了VSIG4水平与血清CA-125水平、VSIG4水平与表明子宫内膜异位症严重程度的因素之间的关联。
与对照组相比，子宫内膜异位囊肿组中VSIG4 mRNA、VSIG4蛋白表达及血清VSIG4浓度显著升高（分别为P = 0.001、0.002和0.049）。用于子宫内膜异位症预测的优化VSIG4临界值分别为0.71、0.32和144.37 pg/mL。使用这些值对队列进行划分后，与低VSIG4水平组相比，高VSIG4水平组的CA-125显著升高（分别为P = 0.010、0.043和0.039）。VSIG4水平与表明子宫内膜异位症严重程度的因素之间无关联。
与非子宫内膜异位肿瘤患者相比，子宫内膜异位症患者中VSIG4的表达增加，且较高的VSIG4水平与较高的血清CA-125水平显著相关。VSIG4可能在子宫内膜异位症的免疫改变中起重要作用。
